Khosla Ventures Acquisition Shares Halted On Code News Pending
$KVSA
Biotechnology: Pharmaceutical Preparations
Health Care
Khosla Ventures Acquisition Shares Halted On Code News Pending
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)
8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)
25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)
MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,
BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot
BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.
BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)